Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STI-6643 |
| Synonyms | |
| Therapy Description |
STI-6643 is an antibody that targets CD47, potentially leading to decreased immune cell depletion, increased tumor cell phagocytosis, and inhibition of tumor growth (PMID: 35664753). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STI-6643 | STI 6643|STI6643 | CD47 Antibody 31 | STI-6643 is an antibody that targets CD47, potentially leading to decreased immune cell depletion, increased tumor cell phagocytosis, and inhibition of tumor growth (PMID: 35664753). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04900519 | Phase I | STI-6643 | Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |